Polycythemia Vera

Dan’s IncyteCARES Story


Hear how IncyteCARES helped Dan

IncyteCARES made a big difference for Dan. Find out how this patient support program for adults taking Jakafi® (ruxolitinib) has provided ongoing support when he needed it most.

Video Transcript

Onscreen text: IncyteCARES…Support Throughout Your Journey on Jakafi® (ruxolitinib)

Dan C
Enrolled in IncyteCARES since 2015

Dan: Early on in the process, the wonderful people at Incyte directed me to IncyteCARES.

Narrator: IncyteCARES is an assistance program that can help support you when you’re starting Jakafi (ruxolitinib) and throughout your treatment journey. As an eligible patient, you can work one-on-one with a registered nurse who has received OCN® certification and can help you address a variety of issues.

Onscreen text: IncyteCARES (Connecting to Access, Reimbursement, Education and Support) is an assistance program that can help support you when you’re starting Jakafi® (ruxolitinib) and throughout your treatment journey.

Eligible patients talk one-on-one with a registered nurse who has received OCN® certification

Onscreen text: Partner with a registered nurse who has received OCN® certification. Eligibility criteria apply. See IncyteCARES.com for details.

Dan: IncyteCARES is so easy to interact with. Whenever we call, it’s a nurse that we’re talking to. They know so much about the disease and about everything associated with this process, and they had this person devoted to me and any questions we had. Anything we needed direction on, they were right there. We didn’t have to know all the questions, and we didn’t have to go far searching for answers. They came to us, and they offered their help and were very aware of the steps they needed to take. IncyteCARES was very helpful and very understanding and aware of the financial impact that these kinds of drugs have on a patient. They helped organize the prescriptions, they helped organize the pharmacy, they helped coordinate that with the doctor’s office. I think IncyteCARES…they care so much about their patients, and they go that next step.

Onscreen text and narrator: IncyteCARES also offers tips, tools, and resources about your condition and Jakafi® (ruxolitinib).

Dan: We have a toll-free number, and they know exactly who we are and what we’ve done in the past.

Onscreen text: 1-855-4-Jakafi (1-855-452-5234). Monday through Friday, 8 AM–8 PM ET.

Dan: It’s an immense comfort. This whole time I’ve felt that I’m part of this team, and this is just a continuation of that. Now, IncyteCARES is on my team.

Onscreen text: IncyteCARES (Connecting to Access, Reimbursement, Education and Support) is an assistance program that can help support you when you’re starting Jakafi® (ruxolitinib) and throughout your treatment journey.

Connect with IncyteCARES today! Visit www.IncyteCARES.com or call 1-855-4-Jakafi (1-855-452-5234) Monday through Friday, 8 AM–8 PM ET.

OCN is a registered trademark of Oncology Nursing Certification Corporation.

The video is sponsored by Incyte Corporation. Jakafi is a registered trademark of Incyte. © 2017, Incyte Corporation. All rights reserved. RUX-2274    10/17

connect-patient

Connect With
a Patient
Like Jack

Connect With a
Patient Like Jack

Register for the Incyte Mentor Program and connect with another patient taking Jakafi.

Email Address

Continue Registering

Expand Collapse

INDICATIONS AND USAGE

INDICATIONS AND USAGE

Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is used to treat adults with certain types of myelofibrosis.

Jakafi is also used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.

Important Safety Information

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Skin cancers: Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Tell your healthcare provider if you develop any new or changing skin lesions.

Increases in cholesterol: You may have changes in your blood cholesterol levels. Your healthcare provider will do blood tests to check your cholesterol levels during your treatment with Jakafi.

The most common side effects of Jakafi include: for certain types of MF and PV – low platelet or red blood cell counts, bruising, dizziness, and headache; and for acute GVHD – low platelet, red or white blood cell counts, infections, and fluid retention.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had tuberculosis (TB) or have been in close contact with someone who has TB, have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had skin cancer, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

Please see the Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.